Clinical trials: Dementia, Senile
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
This is a two-part multiple dose study in healthy male and female (of non-child bearing potential) elderly volunteers, and in Alzheimer's disease patients, to assess the safety, effects on the body, and blood, CSF, and urine drug…
- Trial name
- NCT01795339
- Testing
- AZD3293
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Amblyopia
Evaluation of a Smartphone Application, GoCheckKids™ as a Photo Screening Tool in a Pediatric Population
Objective: Prospective evaluation of GoCheckKids™, a smartphone application ('App') as a photo screening device in a pediatric population to detect amblyopia risk factors (ARFs) Method: Photorefraction images are captured using…
- Trial name
- NCT03119675
- Testing
- GoCheck Kids (iOS), GoCheck Kids (Windows)
- Volunteers
- 358 people
- Sponsor
- Gobiquity Mobile Health
Alzheimer Disease, Neuro-Degenerative Disease
Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent, for the treatment of subjects with Alzheimer's disease.
- Trial name
- ASK-AD (NCT04678453)
- Testing
- SNK01
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- NKGen Biotech, Inc.
Alzheimer's Disease
Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-
The purpose of this study is to investigate the following about donepezil hydrochloride administration in patients with mild or moderate Alzheimer's Disease in clinical practice: cognitive function, Functional Assessment Staging…
- Trial name
- NCT01129596
- Testing
- donepezil hydrochloride
- Where
- 722 sites in Japan
- Volunteers
- 10,238 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
The main purpose of this study is to evaluate the cognitive changes after administration of tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ARGO (NCT01350362)
- Testing
- tideglusib
- Where
- 6 sites in Belgium, Finland and 4 more
- Volunteers
- 306 people
- Sponsor
- Noscira SA
Mild Cognitive Impairment, Dementia
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.
- Trial name
- NCT05104463
- Where
- 15 sites in United States, New Zealand
- Volunteers
- 64 people
- Sponsor
- CuraSen Therapeutics, Inc.
Alzheimer's Disease
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's disease
- Trial name
- NCT01009255
- Testing
- GSK239512
- Where
- 35 sites in Bulgaria, Chile and 6 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Early Alzheimer's Disease
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical…
- Trial name
- Clarity AD (NCT03887455)
- Testing
- Lecanemab IV, Lecanemab SC
- Where
- 247 sites in United States, Australia and 12 more
- Volunteers
- 1,906 people
- Sponsor
- Eisai Inc.
Alzheimer´s Disease
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD).
- Trial name
- AD Biomarker (NCT07741526)
- Testing
- NPI-001
- Where
- 4 sites in Denmark, Iceland
- Volunteers
- 33 people
- Sponsor
- Arctic Therapeutics
Alzheimer Disease, Gastric Retention
Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults
To assess how long memantine hydrochloride (HCl) (50 mg) extended release capsules stay in the stomach as determined by imaging assessment (MRI or abdominal ultrasound).
- Conditions
- Alzheimer Disease, Gastric Retention, Healthy
- Trial name
- NCT03711825
- Testing
- LYN-057, Imaging Assessment (MRI), Imaging Assessment (U/S)
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Lyndra Inc.
Alzheimer's Disease
Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
Open-label treatment with MPC-7869 for participants in a previous randomized study.
- Trial name
- NCT00380276
- Testing
- MPC-7869
- Where
- 90 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Myrexis Inc.
Alzheimer Disease
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the…
- Trial name
- NCT06535308
- Testing
- BnH-015B 5 mg, BnH-015B 10 mg, BnH-015B 20 mg
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- BnH Research
Alzheimer Disease
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease
- Trial name
- NCT02240693
- Testing
- BI 409306
- Where
- 52 sites in United States, Austria and 10 more
- Volunteers
- 128 people
- Sponsor
- Boehringer Ingelheim
Mild Cognitive Impairment Due to Alzheimer's Disease
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study [NCT01931566] with an…
- Trial name
- NCT02284906
- Testing
- Pioglitazone
- Where
- 43 sites in United States, Australia and 2 more
- Volunteers
- 40 people
- Sponsor
- Takeda
Alzheimer's Disease, Mild Cognitive Impairment
Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease
This trial aims to test the hypothesis that 1) a single dose of zinc cysteine in a proprietary gastro-retentive form will produce sustained blood levels of zinc giving a larger bioavailable amount of zinc than an FDA approved…
- Trial name
- NCT01099332
- Testing
- Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adeona Pharmaceuticals
Healthy, Adult
Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
Primary: To evaluate the pharmacologic effect of single doses of SAM-531 on sleep EEG in healthy subjects.
- Trial name
- NCT00519298
- Testing
- SAM-531, Donepezil
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease, Mild Cognitive Impairment
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia
- Trial name
- NCT01465360
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Exonhit
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- PAST-US (NCT04937959)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer's Disease
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4602522 in participants with moderate severity Alzheimer's disease.
- Trial name
- MAyflOwer RoAD (NCT01677754)
- Testing
- RO4602522, Donepezil, Memantine
- Where
- 142 sites in United States, Australia and 10 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease
This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in participants diagnosed with mild to moderate Alzheimer's…
- Trial name
- NCT05811442
- Testing
- 50561 high dose, 50561 low dose
- Where
- 12 sites in China
- Volunteers
- 68 people
- Sponsor
- Beijing Joekai Biotechnology LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.